KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Operating Margin (2016 - 2025)

Historic Operating Margin for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to 12.01%.

  • Alnylam Pharmaceuticals' Operating Margin rose 297400.0% to 12.01% in Q4 2025 from the same period last year, while for Dec 2025 it was 15.92%, marking a year-over-year increase of 237900.0%. This contributed to the annual value of 13.51% for FY2025, which is 213700.0% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Operating Margin stood at 12.01%, which was up 297400.0% from 29.46% recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Operating Margin ranged from a high of 60.26% in Q1 2025 and a low of 104.89% during Q1 2021
  • Over the past 5 years, Alnylam Pharmaceuticals' median Operating Margin value was 36.7% (recorded in 2023), while the average stood at 35.16%.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Operating Margin skyrocketed by 1261200bps in 2023, and later crashed by -438500bps in 2024.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Operating Margin stood at 75.26% in 2021, then rose by 25bps to 56.3% in 2022, then skyrocketed by 53bps to 26.47% in 2023, then surged by 33bps to 17.73% in 2024, then skyrocketed by 168bps to 12.01% in 2025.
  • Its Operating Margin was 12.01% in Q4 2025, compared to 29.46% in Q3 2025 and 2.09% in Q2 2025.